Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Mar 20, 2025; 15(1): 94833
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.94833
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.94833
Navigating the ethical terrain: Off-label and experimental treatments in medical case reports
Madhan Jeyaraman, Naveen Jeyaraman, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, India
Swaminathan Ramasubramanian, Sangeetha Balaji, Department of Orthopaedics, Government Medical College, Omandurar Government Estate, Chennai 600002, India
Author contributions: All authors contributed important intellectual content to the manuscript, reading and approving the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Madhan Jeyaraman, MS, PhD, Assistant Professor, Research Associate, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, India. madhanjeyaraman@gmail.com
Received: March 26, 2024
Revised: July 15, 2024
Accepted: July 18, 2024
Published online: March 20, 2025
Processing time: 186 Days and 22.8 Hours
Revised: July 15, 2024
Accepted: July 18, 2024
Published online: March 20, 2025
Processing time: 186 Days and 22.8 Hours
Core Tip
Core Tip: This article underscores the imperative of ethical integrity in reporting off-label and experimental treatments within medical case reports, advocating for a balanced fusion of innovation and evidence-based medicine. It calls for collective action in developing comprehensive ethical guidelines and enhancing regulatory oversight to prioritize patient safety and uphold scientific rigor.